Spots Global Cancer Trial Database for ramucirumab
Every month we try and update this database with for ramucirumab cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Study of Ramucirumab (LY3009806) in Combination With Paclitaxel in Participants With Gastric Cancer | NCT02514551 | Gastric Adenoca... Gastroesophagea... | Ramucirumab Paclitaxel | 18 Years - | Eli Lilly and Company | |
| RAMucirumab in Combination Wth TAS102 vs. TAS102 Alone in Chemotherapy Refractory Metastatic Colorectal Cancer Patients | NCT03520946 | Colorectal Canc... | Ramucirumab TAS 102 | 18 Years - | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | |
| A Master Protocol (LY900023) That Includes Several Clinical Trials of Drugs for Children and Young Adults With Cancer | NCT05999994 | Neoplasms Child Adolescent | Ramucirumab Cyclophosphamid... Vinorelbine Gemcitabine Docetaxel Abemaciclib Irinotecan Temozolomide | 1 Year - 39 Years | Eli Lilly and Company | |
| A Study of Ramucirumab (LY3009806) in Combination With Capecitabine and Cisplatin in Participants With Stomach Cancer | NCT02314117 | Metastatic Gast... Gastroesophagea... | Ramucirumab Capecitabine Cisplatin Placebo Fluorouracil | 18 Years - | Eli Lilly and Company | |
| A Phase 2 Study of Ramucirumab (LY3009806) in Participants With Gastric or Gastroesophageal Junction (GEJ) Cancer | NCT02443883 | Gastric Adenoca... Gastroesophagea... | Ramucirumab | 18 Years - | Eli Lilly and Company | |
| Carboplatin, Taxane And Ramucirumab for Patients With NSCLC After Pemetrexed or Pembrolizumab Maintenance | NCT04332367 | Non-small Cell ... | Carboplatin Paclitaxel Ramucirumab | 18 Years - | Abramson Cancer Center at Penn Medicine | |
| Ramucirumab or Anti-PDGFR Alpha Monoclonal Antibody IMC-3G3 in Treating Patients With Recurrent Glioblastoma Multiforme | NCT00895180 | Adult Glioblast... | olaratumab ramucirumab | 18 Years - | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| A Study of Ramucirumab (LY3009806) Plus Docetaxel in Participants With Urothelial Cancer | NCT02426125 | Urothelial Carc... | Ramucirumab Docetaxel Placebo | 18 Years - | Eli Lilly and Company | |
| A Study of Ramucirumab (LY3009806) Versus Placebo in Participants With Hepatocellular Carcinoma and Elevated Baseline Alpha-Fetoprotein | NCT02435433 | Hepatocellular ... | Ramucirumab Placebo | 18 Years - | Eli Lilly and Company | |
| Ph1b Study of Oraxol in Comb. w. Ramucirumab in Patients w. Gastric, Gastro-esophageal, or Esophageal Cancers | NCT02970539 | Gastric Cancer Esophageal Canc... Gastro-esophage... | Oraxol Ramucirumab | 18 Years - | Athenex, Inc. | |
| FLOT vs. FLOT/Ramucirumab for Perioperative Therapy of Gastric or GEJ Cancer (RAMSES) | NCT02661971 | Stomach Cancer Gastroesophagea... | Docetaxel Oxaliplatin Calciumfolinat 5-Fluorouracil Ramucirumab | 18 Years - 70 Years | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | |
| A Study of Ramucirumab in Participants With Gastric or Gastroesophageal Junction Adenocarcinoma | NCT02539225 | Metastatic Gast... Gastroesophagea... | Ramucirumab Placebo S-1 Oxaliplatin Paclitaxel | 20 Years - | Eli Lilly and Company | |
| Ramucirumab Plus FOLFIRI Versus Ramucirumab Plus Paclitaxel in Patients With Advanced or Metastatic Gastric Cancer, Who Failed One Prior Line of Palliative Chemotherapy | NCT03081143 | Advanced Gastri... | FOLFIRI Ramucirumab Paclitaxel | 18 Years - | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | |
| Ramucirumab and Pembrolizumab for the Treatment of EGFR Mutant Recurrent or Metastatic Non-small Cell Lung Cancer | NCT04120454 | Metastatic Lung... Recurrent Lung ... Stage IV Lung C... Stage IVA Lung ... Stage IVB Lung ... | Pembrolizumab Ramucirumab | 18 Years - | Ohio State University Comprehensive Cancer Center | |
| Real-world Data (RWD) of Ramucirumab Plus Paclitaxel | NCT04915807 | Gastric Cancer Gastroesophagea... | Ramucirumab and... Taxane, irinote... | 19 Years - | Hallym University Medical Center | |
| Avelumab + Paclitaxel/ Ramucirumab (RAP) as Second Line Treatment in Gastro-esophageal Adenocarcinoma | NCT03966118 | Gastroesophagea... Adenocarcinoma ... | Avelumab Ramucirumab Paclitaxel | 18 Years - | Charite University, Berlin, Germany | |
| Novel SEQUEnced Immunotherapy With Anti-angiogenesis and Chemotherapy in Advanced gastroesophageaL Adenocarcinoma | NCT04069273 | Gastric Cancer GastroEsophagea... Adenocarcinoma | Pembrolizumab M... Ramucirumab Paclitaxel | 18 Years - | Hoosier Cancer Research Network | |
| Phase II Randomized Trial of mFOLFIRINOX +/- Ramucirumab in Advanced Pancreatic Cancer | NCT02581215 | Pancreatic Canc... | mFOLFIRINOX Ramucirumab Placebo | 18 Years - | Hoosier Cancer Research Network | |
| Study of Ramucirumab in Ovarian Cancer | NCT00721162 | Ovarian Cancer Fallopian Tube ... Primary Periton... | Ramucirumab | 18 Years - | Eli Lilly and Company | |
| A Study of Ramucirumab in Participants With Gastric, Esophageal, and Gastroesophageal Cancer | NCT01246960 | Stomach Cancer Esophageal Canc... | Ramucirumab Placebo Oxaliplatin Leucovorin 5-Fluorouracil | 18 Years - | Eli Lilly and Company | |
| A Study of Ramucirumab or Icrucumab in Colorectal Cancer | NCT01111604 | Colon Cancer Rectal Cancer | Ramucirumab Icrucumab mFOLFOX-6 | 18 Years - | Eli Lilly and Company | |
| Ramucirumab Plus FOLFIRI Versus Ramucirumab Plus Paclitaxel in Patients With Advanced or Metastatic Gastric Cancer, Who Failed One Prior Line of Palliative Chemotherapy | NCT03081143 | Advanced Gastri... | FOLFIRI Ramucirumab Paclitaxel | 18 Years - | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | |
| Second-Line Chemotherapy With Ramucirumab +/- Paclitaxel in Elderly Advanced Gastric or Gastroesophageal Junction Cancer Patients | NCT03760822 | Stomach Cancer Stomach Neoplas... Gastric Cancer Gastroesophagea... | Ramucirumab Paclitaxel | 70 Years - | Federation Francophone de Cancerologie Digestive | |
| A Study of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Cancer (G/GEJ) or Esophageal Cancer (Morpheus-Gastric and Esophageal Cancer) | NCT03281369 | Gastric Adenoca... | 5-Fluorouracil ... Leucovorin Oxaliplatin Atezolizumab Cobimetinib Ramucirumab Paclitaxel PEGylated recom... BL-8040 Linagliptin Atezolizumab Cobimetinib Cisplatin Tiragolumab 5-Fluorouracil ... | 18 Years - | Hoffmann-La Roche | |
| Clinical Trial of the Safety and Efficacy of the Addition of Ramucirumab to Nab-paclitaxel in Previously Treated Patients With Advanced Non-small Cell Lung Cancer (NSCLC) | NCT02730247 | Non-small Cell ... | ramucirumab nab-paclitaxel | 18 Years - | University of Pittsburgh | |
| A Study of Ramucirumab (LY3009806) or Merestinib (LY2801653) in Advanced or Metastatic Biliary Tract Cancer | NCT02711553 | Biliary Tract C... Metastatic Canc... Advanced Cancer | Ramucirumab Merestinib Cisplatin Gemcitabine Placebo Oral Placebo IV | 18 Years - | Eli Lilly and Company | |
| RAMucirumab in Combination Wth TAS102 vs. TAS102 Alone in Chemotherapy Refractory Metastatic Colorectal Cancer Patients | NCT03520946 | Colorectal Canc... | Ramucirumab TAS 102 | 18 Years - | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | |
| CAMPFIRE: A Study of Ramucirumab (LY3009806) in Children and Young Adults With Desmoplastic Small Round Cell Tumor | NCT04145349 | Desmoplastic Sm... | Ramucirumab Cyclophosphamid... Vinorelbine | 12 Months - 29 Years | Eli Lilly and Company | |
| RAmucirumab Combined wIth Standard Nab-paclitaxel and Gemcitabine as First-line Chemotherapy in Patients With Advanced Pancreatic Adenocarcinoma | NCT03745430 | Pancreatic Aden... | Ramucirumab | 18 Years - | Hellenic Cooperative Oncology Group | |
| Study of Crenolanib With Ramucirumab and Paclitaxel for Advanced Esophagogastric Adenocarcinoma | NCT03193918 | Esophagogastric... | Crenolanib Ramucirumab Paclitaxel | 18 Years - | Arog Pharmaceuticals, Inc. | |
| Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial | NCT06203600 | Advanced Esopha... Advanced Gastri... Advanced Gastro... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Metastatic Esop... Metastatic Gast... Metastatic Gast... Unresectable Es... Unresectable Ga... Unresectable Ga... | Biospecimen Col... Computed Tomogr... Magnetic Resona... Nivolumab Paclitaxel Questionnaire A... Ramucirumab | 18 Years - | National Cancer Institute (NCI) | |
| Study of Crenolanib With Ramucirumab and Paclitaxel for Advanced Esophagogastric Adenocarcinoma | NCT03193918 | Esophagogastric... | Crenolanib Ramucirumab Paclitaxel | 18 Years - | Arog Pharmaceuticals, Inc. | |
| Ramucirumab and Atezolizumab After Progression on Any Immune Checkpoint Blocker in NSCLC | NCT03689855 | Non-small Cell ... Non Small Cell ... NSCLC | Ramucirumab Atezolizumab Peripheral bloo... Biopsy | 18 Years - | Washington University School of Medicine | |
| A Study of Ramucirumab in Participants With Metastatic Renal Cell Carcinoma | NCT00515697 | Metastatic Rena... | Ramucirumab | 18 Years - | Eli Lilly and Company | |
| Ramucirumab Use in Combination With Paclitaxel in Gastric or Gastroesophageal Junction Adenocarcinoma; Temporary Authorization for Use (ATU) in France | NCT02307812 | Gastric Cancer Gastroesophagea... | Ramucirumab Paclitaxel | - | Eli Lilly and Company | |
| Ramucirumab and Pembrolizumab vs Pembrolizumab Monotherapy in PD-L1 Positive Head and Neck Squamous-Cell Carcinoma | NCT05980000 | Recurrent Head ... Recurrent Head ... Recurrent Head ... Metastatic Head... Metastatic Head... HNSCC | Ramucirumab Pembrolizumab | 18 Years - | Washington University School of Medicine | |
| Carboplatin and Paclitaxel With or Without Ramucirumab in Treating Patients With Locally Advanced, Recurrent, or Metastatic Thymic Cancer That Cannot Be Removed by Surgery | NCT03694002 | Locally Advance... Metastatic Thym... Recurrent Thymi... Unresectable Th... | Carboplatin Paclitaxel Ramucirumab | 18 Years - | SWOG Cancer Research Network | |
| A Study of Ramucirumab (LY3009806) Versus Placebo in Participants With Hepatocellular Carcinoma and Elevated Baseline Alpha-Fetoprotein | NCT02435433 | Hepatocellular ... | Ramucirumab Placebo | 18 Years - | Eli Lilly and Company | |
| A Study of BGB-A445 in Combination With Other Investigational Agents in Participants With Non-Small Cell Lung Cancer | NCT06029127 | Non-Small Cell ... | BGB-A445 Docetaxel Ramucirumab BGB-15025 | 18 Years - | BeiGene | |
| Paclitaxel and Ramucirumab +/- Zanidatamab in HER2 Postive Advanced Gastroesophageal Adenocarcinoma | NCT06043427 | Gastroesophagea... | Paclitaxel Ramucirumab Zanidatamab | 18 Years - | Canadian Cancer Trials Group | |
| Study of IMC-1121B (Ramucirumab) With Best Supportive Care in Participants With Gastric Cancer and Adenocarcinoma | NCT00917384 | Gastric Cancer Adenocarcinoma | ramucirumab Placebo Best Supportive... | 18 Years - | Eli Lilly and Company | |
| A Study in Second Line Metastatic Colorectal Cancer | NCT01183780 | Colorectal Canc... | Ramucirumab Placebo Irinotecan Folinic Acid 5-Fluorouracil | 18 Years - | Eli Lilly and Company | |
| Trastuzumab Beyond Progression in HER2 Positive Metastatic Gastric Cancer | NCT03766607 | Gastric Cancer | Trastuzumab Ramucirumab Paclitaxel | 19 Years - | Korean South West Oncology Group | |
| Abemaciclib Plus Ramucirumab for Esophageal/Gastroesophageal Junction Ca | NCT04921904 | Metastatic Esop... Metastatic Gast... | Abemaciclib Ramucirumab | 18 Years - | Baylor Research Institute | |
| Nivolumab Plus Ramucirumab in Patients With Recurrent, Advanced, Metastatic NSCLC | NCT03527108 | Non Small Cell ... | Nivolumab Ramucirumab | 18 Years - | Fox Chase Cancer Center | |
| A Study of agenT-797 in Combination With Botensilimab, Balstilimab, Ramucirumab, and Paclitaxel for People With Esophageal, Gastric, or Gastro-esophageal Junction Cancer | NCT06251973 | Metastatic Esop... Advanced Unrese... Metastatic Gast... Metastatic Gast... Metastatic Esop... Metastatic Esop... Metastatic Gast... Metastatic Gast... Unresectable Es... Unresectable Es... Unresectable Ga... Unresectable Ga... Unresectable Ga... | AgenT-797 Botensilimab Balstilimab Ramucirumab Paclitaxel | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| An Investigational Immuno-therapy Study of Relatlimab Plus Nivolumab Compared to Various Standard-of-Care Therapies in Previously Treated Participants With Recurrent, Advanced or Metastatic Gastric Cancer or Gastroesophageal Junction Adenocarcinoma | NCT03704077 | Gastric Cancer Cancer of the S... Stomach Cancer Gastroesophagea... | Relatlimab + Ni... Nivolumab Paclitaxel Ramucirumab | 18 Years - | Bristol-Myers Squibb | |
| Phase II Study of Ramucirumab With Chemotherapy in Patients With Metastatic Gastroesophageal Junction and Gastric Cancer | NCT02726399 | Gastric Cancer Gastroesophagea... | Ramucirumab Trastuzumab Capecitabine Cisplatin | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Study With Paclitaxel +/- Ramucirumab in Patients With Squamous-cell Carcinoma of the Esophagus After Prior Therapy | NCT03762564 | Squamous Cell C... | Ramucirumab Paclitaxel | 18 Years - | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | |
| Irinotecan Hydrochloride and Cetuximab With or Without Ramucirumab in Treating Patients With Advanced Colorectal Cancer With Progressive Disease After Treatment With Bevacizumab-Containing Chemotherapy | NCT01079780 | Colorectal Canc... | cetuximab ramucirumab irinotecan hydr... | 18 Years - | Eastern Cooperative Oncology Group | |
| A Study of Ramucirumab (LY3009806) in Combination With Erlotinib in Previously Untreated Participants With EGFR Mutation-Positive Metastatic NSCLC (RELAY) | NCT02411448 | Metastatic Non-... | Ramucirumab Placebo Erlotinib Gefitinib Osimertinib | 18 Years - | Eli Lilly and Company | |
| Irinotecan Hydrochloride and Cetuximab With or Without Ramucirumab in Treating Patients With Advanced Colorectal Cancer With Progressive Disease After Treatment With Bevacizumab-Containing Chemotherapy | NCT01079780 | Colorectal Canc... | cetuximab ramucirumab irinotecan hydr... | 18 Years - | Eastern Cooperative Oncology Group | |
| Phase 2 DoceRamPem for Patients With Metastatic or Recurrent NSCLC Who Progressed on Platinum-Doublet and PD-1/PD-L1 Blockade | NCT04340882 | Metastatic Non-... Recurrent Non-S... Stage IV Lung C... Stage IVA Lung ... Stage IVB Lung ... | Docetaxel Pembrolizumab Ramucirumab | 18 Years - | Emory University | |
| CAMPFIRE: A Study of Ramucirumab (LY3009806) in Children and Young Adults With Desmoplastic Small Round Cell Tumor | NCT04145349 | Desmoplastic Sm... | Ramucirumab Cyclophosphamid... Vinorelbine | 12 Months - 29 Years | Eli Lilly and Company | |
| International Expanded Access Program to Provide Ramucirumab for the Treatment of Metastatic Gastric Cancer | NCT02065765 | Metastatic Gast... Metastatic Aden... | Ramucirumab | 18 Years - | Eli Lilly and Company | |
| Platinum-Based Chemotherapy Plus Ramucirumab in Patients With Advanced NSCLC Who Have Progressed on First Line Anti-PD-1 Immunotherapy | NCT03904108 | Carcinoma, Non-... | Ramucirumab | 18 Years - | Stony Brook University | |
| Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial) | NCT06031688 | Recurrent Lung ... Stage IV Lung C... | Biospecimen Col... Computed Tomogr... Lymphoscintigra... Magnetic Resona... Ramucirumab Tepotinib | - | SWOG Cancer Research Network | |
| A Study of Ramucirumab (IMC-1121B) With Paclitaxel and Carboplatin in Non-small Cell Lung Cancer | NCT00735696 | Non Small Cell ... | Ramucirumab Paclitaxel Carboplatin | 18 Years - | Eli Lilly and Company | |
| Ramucirumab or Anti-PDGFR Alpha Monoclonal Antibody IMC-3G3 in Treating Patients With Recurrent Glioblastoma Multiforme | NCT00895180 | Adult Glioblast... | olaratumab ramucirumab | 18 Years - | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| PANGEA-IMBBP: Personalized Antibodies for Gastro-Esophageal Adenocarcinoma - A 1st Pilot Metastatic Trial of Biologics Beyond Progression | NCT02213289 | Adenocarcinoma | Trastuzumab ABT-806 Bemarituzumab Ramucirumab Nivolumab Standard cytoth... | 18 Years - | University of Chicago | |
| Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial) | NCT05642572 | Recurrent Lung ... Stage IV Lung C... | Biospecimen Col... Capmatinib Computed Tomogr... Magnetic Resona... Osimertinib Ramucirumab | 18 Years - | SWOG Cancer Research Network | |
| Assessment of Ramucirumab Plus Paclitaxel as Switch MANteInance Versus Continuation of First-line Chemotherapy in Patients With Advanced HER-2 Negative Gastric or Gastroesophageal Junction Cancers | NCT02934464 | Stomach Neoplas... | RAMUCIRUMAB Paclitaxel FOLFOX 4 mFOLFOX 6 XELOX | 18 Years - | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | |
| Quaratusugene Ozeplasmid (Reqorsa) in Combination With Pembrolizumab in Previously Treated Non-Small Lung Cancer | NCT05062980 | Non Small Cell ... | quaratusugene o... pembrolizumab docetaxel ramucirumab Investigator's ... | 18 Years - | Genprex, Inc. | |
| A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors | NCT03872947 | Solid Tumor Colorectal Canc... Cholangiocarcin... Bladder Cancer Ovarian Cancer Gastric Cancer Palpable Subcut... Renal Cell Carc... Melanoma Epithelial Ovar... Primary Periton... Fallopian Tube ... | TRK-950 TRK-950 TRK-950 Irinotecan Leucovorin 5-FU Gemcitabine Cisplatin Carboplatin Ramucirumab Paclitaxel Nivolumab Pembrolizumab Imiquimod Cream Bevacizumab PLD | 18 Years - | Toray Industries, Inc | |
| A Double Blind, Placebo Controlled, Randomized Phase II Study Evaluating Gemcitabine With or Without Ramucirumab , for II Line Treatment MPM | NCT03560973 | Mesothelioma | Gemcitabine Ramucirumab | 18 Years - | Gruppo Oncologico Italiano di Ricerca Clinica | |
| PANGEA-IMBBP: Personalized Antibodies for Gastro-Esophageal Adenocarcinoma - A 1st Pilot Metastatic Trial of Biologics Beyond Progression | NCT02213289 | Adenocarcinoma | Trastuzumab ABT-806 Bemarituzumab Ramucirumab Nivolumab Standard cytoth... | 18 Years - | University of Chicago | |
| Olaparib and Ramucirumab in Treating Patients With Metastatic or Locally Recurrent Gastric or Gastroesophageal Junction Cancer That Cannot Be Removed by Surgery | NCT03008278 | Metastatic Esop... Metastatic Gast... Metastatic Gast... Recurrent Esoph... Recurrent Gastr... Recurrent Gastr... Stage III Esoph... Stage III Gastr... Stage IV Esopha... Stage IV Gastri... Unresectable Es... Unresectable Ga... Unresectable Ga... | Olaparib Ramucirumab | 18 Years - | National Cancer Institute (NCI) | |
| A Study in Advanced Cancers Using Ramucirumab (LY3009806) and Other Targeted Agents | NCT02745769 | Advanced Cancer Colorectal Canc... Mantle Cell Lym... | Ramucirumab Merestinib Abemaciclib | 18 Years - | Eli Lilly and Company | |
| A Study of LY3127804 With Ramucirumab in Participants With Advanced Solid Tumors | NCT02597036 | Solid Tumors | LY3127804 Ramucirumab Paclitaxel | 18 Years - | Eli Lilly and Company | |
| A Study of Ramucirumab or Icrucumab in Colorectal Cancer | NCT01111604 | Colon Cancer Rectal Cancer | Ramucirumab Icrucumab mFOLFOX-6 | 18 Years - | Eli Lilly and Company | |
| Ramucirumab/Paclitaxel as Second-line Treatment in Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma With Integrative Genomic Analysis | NCT02628951 | Gastric Adenoca... Gastroesophagea... | Ramucirumab Paclitaxel | 18 Years - | Samsung Medical Center | |
| Testing of TAK228 (MLN0128, Sapanisertib) Plus Docetaxel to the Usual Standard of Care for Advanced Squamous Cell Lung Cancer (A Lung-MAP Treatment Trial) | NCT04267913 | Lung Squamous C... Recurrent Lung ... Stage IV Lung C... Stage IVA Lung ... Stage IVB Lung ... | Dexamethasone Docetaxel Ramucirumab Sapanisertib | - | SWOG Cancer Research Network | |
| Ph1b Study of Oraxol in Comb. w. Ramucirumab in Patients w. Gastric, Gastro-esophageal, or Esophageal Cancers | NCT02970539 | Gastric Cancer Esophageal Canc... Gastro-esophage... | Oraxol Ramucirumab | 18 Years - | Athenex, Inc. | |
| A Study of Evorpacept (ALX148) in Patients With Advanced HER2+ Gastric Cancer (ASPEN-06) | NCT05002127 | Gastric Cancer Gastroesophagea... Gastric Adenoca... | Evorpacept (ALX... Trastuzumab Ramucirumab Paclitaxel | 18 Years - | ALX Oncology Inc. | |
| A Study of Ramucirumab (IMC-1121B) in Participants With Breast Cancer | NCT01256567 | Breast Cancer Metastatic Brea... | Ramucirumab Docetaxel | 20 Years - | Eli Lilly and Company | |
| A Study of Docetaxel and Ramucirumab Versus Docetaxel and Placebo in the Treatment of Stage IV Non-Small Cell Lung Cancer | NCT01703091 | Non-small Cell ... | Ramucirumab Placebo Docetaxel | 20 Years - | Eli Lilly and Company | |
| Ramucirumab + Pembrolizumab in Patients With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma | NCT03650764 | Head and Neck S... | Ramucirumab Pembrolizumab EORTC QLQ-30 FACT H&N Peripheral bloo... | 18 Years - | Washington University School of Medicine | |
| A Study of Lorlatinib in Combination With Ramucirumab in People With Lung Cancer | NCT06007937 | Non Small Cell ... Metastatic Recurrent | Lorlatinib Ramucirumab | 19 Years - | Memorial Sloan Kettering Cancer Center | |
| Abemaciclib Plus Ramucirumab for Esophageal/Gastroesophageal Junction Ca | NCT04921904 | Metastatic Esop... Metastatic Gast... | Abemaciclib Ramucirumab | 18 Years - | Baylor Research Institute | |
| A Study of Sintilimab Plus Ramucirumab as First-line Treatment for G/EGJ Adenocarcinoma (ORIENT-106) | NCT04675983 | Gastric Adenoca... | Sintilimab Ramucirumab Cisplatin 5-fluorouracil Oxaliplatin Capecitabine | 18 Years - 75 Years | Innovent Biologics (Suzhou) Co. Ltd. |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
